Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Gastrointestinal 4Breast 4Thoracic 3Genitourinary 3Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Other 1Myeloid 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1

Conditions

Nose Neoplasms 1Esthesioneuroblastoma, Olfactory 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ibuprofen × CNS × Clear all
NCT05012098 2025-08-08

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 14 charts
CNS

Nose Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡